Adjunctive treatments in pediatric acute respiratory distress syndrome

Expert Review of Respiratory Medicine

Volumn 8, Issue 6, 2014, Pages 703-716

  Mok, Yee Hui ^a   Lee, Jan Hau ^a,b   Rehder, Kyle J ^c   Turner, David A ^c  

^a KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c DUKE CHILDREN S HOSPITAL   (United States)

Author keywords

acute respiratory distress syndrome; children; nitric oxide; pediatric; prone positioning; prostaglandin; pulmonary hypertension; steroid; surfactant

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC GMP; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN; STEROID; SURFACTANT; VASODILATOR AGENT; LUNG SURFACTANT;

ADULT RESPIRATORY DISTRESS SYNDROME; CHILDHOOD DISEASE; DISEASE SEVERITY; HUMAN; HYPOXEMIA; LUNG BLOOD FLOW; LUNG EDEMA; LUNG FUNCTION; LUNG VENTILATION; LUNG VOLUME; MULTICENTER STUDY (TOPIC); OXYGENATION; PATIENT SELECTION; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); TIDAL VOLUME; ARTIFICIAL VENTILATION; BODY POSTURE; CHILD; RESPIRATORY DISTRESS SYNDROME, ADULT;

CHILD; HUMANS; PRONE POSITION; PULMONARY SURFACTANTS; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 84910619789     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2014.948854     Document Type: Review

References (161)

1. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342(18):1334-49
2. Tomashefski JF Jr. Pulmonary pathology of the adult respiratory distress syndrome. Clin Chest Med 1990;11(4):593-619
3. Park WY, Goodman RB, Steinberg KP, et al. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2001;164(10 Pt 1):1896-903
4. Goodman RB, Strieter RM, Martin DP, et al. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1996;154(3 Pt 1):602-11
5. Steinberg KP, Milberg JA, Martin TR, et al. Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome. Am J Respir Crit Care Med 1994;150(1):113-22
6. Lopez-Fernandez Y, Azagra AM, de la Oliva P, et al. Pediatric acute lung injury epidemiology and natural history study: incidence and outcome of the acute respiratory distress syndrome in children. Crit Care Med 2012;40(12):3238-45.
7. Erickson S, Schibler A, Numa A, et al. Acute lung injury in pediatric intensive care in Australia and New Zealand: a prospective, multicenter, observational study. Pediatr Crit Care Med 2007;8(4): 317-23
8. Flori HR, Glidden DV, Rutherford GW, Matthay MA. Pediatric acute lung injury: prospective evaluation of risk factors associated with mortality. Am J Respir Crit Care Med 2005;171(9):995-1001
9. Zimmerman JJ, Akhtar SR, Caldwell E, Rubenfeld GD. Incidence and outcomes of pediatric acute lung injury. Pediatrics 2009; 124(1):87-95
10. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149(3 Pt 1):818-24
11. Ferguson ND, Fan E, Camporota L, et al. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med 2012;38(10):1573-82.
12. De Luca D, Piastra M, Chidini G, et al. The use of the Berlin definition for acute respiratory distress syndrome during infancy and early childhood: multicenter evaluation and expert consensus. Intensive Care Med 2013;39(12):2083-91
13. Santschi M, Randolph AG, Rimensberger PC, Jouvet P. Mechanical ventilation strategies in children with acute lung injury: a survey on stated practice pattern. Pediatr Crit Care Med 2013; 14(7):e332-7
14. Piehl MA, Brown RS. Use of extreme position changes in acute respiratory failure. Crit Care Med 1976;4(1):13-14
15. Pappert D, Rossaint R, Slama K, et al. Influence of positioning on ventilation-perfusion relationships in severe adult respiratory distress syndrome. Chest 1994;106(5):1511-16
16. Pelosi P, Tubiolo D, Mascheroni D, et al. Effects of the prone position on respiratory mechanics and gas exchange during acute lung injury. Am J Respir Crit Care Med 1998;157(2):387-93
17. Pelosi P, Croci M, Calappi E, et al. The prone positioning during general anesthesia minimally affects respiratory mechanics while improving functional residual capacity and increasing oxygen tension. Anesth Analg 1995;80(5):955-60
18. Numa AH, Hammer J, Newth CJ. Effect of prone and supine positions on functional residual capacity, oxygenation, and respiratory mechanics in ventilated infants and children. Am J Respir Crit Care Med 1997;156(4 Pt 1):1185-9
19. Douglas WW, Rehder K, Beynen FM, et al. Improved oxygenation in patients with acute respiratory failure: the prone position. Am Rev Respir Dis 1977;115(4):559-66
20. Wagaman MJ, Shutack JG, Moomjian AS, et al. Improved oxygenation and lung compliance with prone positioning of neonates. J Pediatr 1979;94(5):787-91
21. Pelosi P, D'Andrea L, Vitale G, et al. Vertical gradient of regional lung inflation in adult respiratory distress syndrome. Am J Respir Crit Care Med 1994;149(1):8-13
22. Froese AB, Bryan AC. Effects of anesthesia and paralysis on diaphragmatic mechanics in man. Anesthesiology 1974;41(3):242-55
23. Lamm WJ, Graham MM, Albert RK. Mechanism by which the prone position improves oxygenation in acute lung injury. Am J Respir Crit Care Med 1994;150(1): 184-93
24. Gattinoni L, Pelosi P, Vitale G, et al. Body position changes redistribute lung computed-tomographic density in patients with acute respiratory failure. Anesthesiology 1991;74(1):15-23
25. Mure M, Domino KB, eindahl SG, et al. Regional ventilation-perfusion distribution is more uniform in the prone position. J Appl Physiol (1985) 2000:88(3):1076-83
26. Gattinoni L, Tognoni G, Pesenti A, et al. Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med 2001;345(8):568-73.
27. Gattinoni L, Vagginelli F, Carlesso E, et al. Decrease in Paco2 with prone position is predictive of improved outcome in acute respiratory distress syndrome. Crit Care Med 2003;31(12):2727-33
28. Guerin C, Gaillard S, Lemasson S, et al. Effects of systematic prone positioning in hypoxemic acute respiratory failure: a randomized controlled trial. JAMA 2004; 292(19):2379-87
29. Taccone P, Pesenti A, Latini R, et al. Prone positioning in patients with moderate and severe acute respiratory distress syndrome: a randomized controlled trial. JAMA 2009; 302(18):1977-84
30. Casado-Flores J, Martinez de Azagra A, Ruiz-Lopez MJ, et al. Pediatric ARDS: effect of supine-prone postural changes on oxygenation. Intensive Care Med 2002; 28(12):1792-6
31. Sud S, Sud M, Friedrich JO, Adhikari NK. Effect of mechanical ventilation in the prone position on clinical outcomes in patients with acute hypoxemic respiratory failure: a systematic review and meta-Analysis. CMAJ 2008;178(9):1153-61
32. Guerin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med 2013; 368(23):2159-68
33. Gattinoni L, Pesenti A, Carlesso E. Body position changes redistribute lung computed-tomographic density in patients with acute respiratory failure: impact and clinical fallout through the following 20 years. Intensive Care Med 2013;39(11): 1909-15
34. Gattinoni L, Taccone P, Carlesso E, Marini JJ. Prone position in acute respiratory distress syndrome. Rationale, indications, and limits. Am J Respir Crit Care Med 2013;188(11):1286-93
35. Bancalari E, Clausen J. Pathophysiology of changes in absolute lung volumes. Eur Respir J 1998;12(1):248-58
36. von Ungern-Sternberg BS, Hammer J, Frei FJ, et al. Prone equals prone? Impact of positioning techniques on respiratory function in anesthetized and paralyzed healthy children. Intensive Care Med 2007; 33(10):1771-7
37. Curley MA, Hibberd PL, Fineman LD, et al. Effect of prone positioning on clinical outcomes in children with acute lung injury: a randomized controlled trial. JAMA 2005; 294(2):229-37.
38. Gillies D, Wells D, Bhandari AP. Positioning for acute respiratory distress in hospitalised infants and children. Cochrane Database Syst Rev 2012;7:CD003645
39. Relvas MS, Silver PC, Sagy M. Prone positioning of pediatric patients with ARDS results in improvement in oxygenation if maintained > 12 h daily. Chest 2003; 124(1):269-74
40. Goettler CE, Pryor JP, Reilly PM. Brachial plexopathy after prone positioning. Crit Care 2002;6(6):540-2
41. Kaisers U, Busch T, Deja M, et al. Selective pulmonary vasodilation in acute respiratory distress syndrome. Crit Care Med 2003; 31(4):S337-42
42. Villar J, Blazquez MA, Lubillo S, et al. Pulmonary hypertension in acute respiratory failure. Crit Care Med 1989;17(6):523-6
43. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-Arginine. Nature 1988; 333(6174):664-6
44. Dellinger RP, Zimmerman JL, Taylor RW, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med 1998;26(1):15-23
45. Rossaint R, Falke KJ, Lopez F, et al. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328(6):399-405
46. Clark RH, Kueser TJ, Walker MW, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med 2000;342(7):469-74
47. Davidson D, Barefield ES, Kattwinkel J, et al. The I-NO/PPHN Study Group. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. Pediatrics 1998;101(3 Pt 1):325-34
48. Miller OI, Tang SF, Keech A, et al. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. Lancet 2000;356(9240):1464-9
49. Solina A, Papp D, Ginsberg S, et al. A comparison of inhaled nitric oxide and milrinone for the treatment of pulmonary hypertension in adult cardiac surgery patients. J Cardiothorac Vasc Anesth 2000; 14(1):12-17
50. Tang SF, Sherwood MC, Miller OI. Randomised trial of three doses of inhaled nitric oxide in acute respiratory distress syndrome. Arch Dis Child 1998;79(5): 415-18
51. Lundin S, Mang H, Smithies M, et al. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. The European Study Group of Inhaled Nitric Oxide. Intensive Care Med 1999;25(9):911-19
52. Okamoto K, Hamaguchi M, Kukita I, et al. Efficacy of inhaled nitric oxide in children with ARDS. Chest 1998;114(3):827-33
53. Demirakca S, Dotsch J, Knothe C, et al. Inhaled nitric oxide in neonatal and pediatric acute respiratory distress syndrome: dose response, prolonged inhalation, and weaning. Crit Care Med 1996;24(11): 1913-19
54. Rossaint R, Gerlach H, Schmidt-Ruhnke H, et al. Efficacy of inhaled nitric oxide in patients with severe ARDS. Chest 1995; 107(4):1107-15
55. Abman SH, Griebel JL, Parker DK, et al. Acute effects of inhaled nitric oxide in children with severe hypoxemic respiratory failure. J Pediatr 1994;124(6):881-8
56. Germann P, Poschl G, Leitner C, et al. Additive effect of nitric oxide inhalation on the oxygenation benefit of the prone position in the adult respiratory distress syndrome. Anesthesiology 1998;89(6): 1401-6
57. Johannigman JA, Davis K Jr, Miller SL, et al. Prone positioning and inhaled nitric oxide: synergistic therapies for acute respiratory distress syndrome. J Trauma 2001;50(4):589-95; discussion 595-586
58. Johannigman JA, Davis K Jr, Campbell RS, et al. Positive end-expiratory pressure and response to inhaled nitric oxide: changing nonresponders to responders. Surgery 2000; 127(4):390-4
59. Okamoto K, Kukita I, Hamaguchi M, et al. Combined effects of inhaled nitric oxide and positive end-expiratory pressure during mechanical ventilation in acute respiratory distress syndrome. Artif Organs 2000;24(5): 390-5
60. Dobyns EL, Anas NG, Fortenberry JD, et al. Interactive effects of high-frequency oscillatory ventilation and inhaled nitric oxide in acute hypoxemic respiratory failure in pediatrics. Crit Care Med 2002;30(11): 2425-9
61. Krafft P, Fridrich P, Fitzgerald RD, et al. Effectiveness of nitric oxide inhalation in septic ARDS. Chest 1996;109(2):486-93
62. Manktelow C, Bigatello LM, Hess D, Hurford WE. Physiologic determinants of the response to inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesthesiology 1997;87(2): 297-307
63. Dobyns EL, Cornfield DN, Anas NG, et al. Multicenter randomized controlled trial of the effects of inhaled nitric oxide therapy on gas exchange in children with acute hypoxemic respiratory failure. J Pediatr 1999;134(4):406-12
64. Taylor RW, Zimmerman JL, Dellinger RP, et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA 2004; 291(13):1603-9
65. Adhikari NK, Burns KE, Friedrich JO, et al. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-Analysis. BMJ 2007;334(7597):779
66. Cueto E, Lopez-Herce J, Sanchez A, Carrillo A. Life-threatening effects of discontinuing inhaled nitric oxide in children. Acta Paediatr 1997;86(12):1337-9
67. Afshari A, Brok J, Moller AM, Wetterslev J. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adults. Cochrane Database Syst Rev 2010(7):CD002787
68. Vane JR, Botting RM. Regulatory mechanisms of the vascular endothelium: an update. Pol J Pharmacol 1994;46(6): 499-21
69. Tateson JE, Moncada S, Vane JR. Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins 1977;13(3):389-97
70. Krishnan U. Management of pulmonary arterial hypertension in the neonatal unit. Cardiol Rev 2010;18(2):73-5
71. Ivy DD. Prostacyclin in the intensive care setting. Pediatr Crit Care Med 2010; 11(Suppl 2):S41-5
72. McLaughlin VV, Palevsky HI. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension. Clin Chest Med 2013;34(4):825-40
73. Walmrath D, Schneider T, Pilch J, et al. Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet 1993;342(8877): 961-2
74. Walmrath D, Schneider T, Schermuly R, et al. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996;153(3):991-6
75. Pappert D, Busch T, Gerlach H, et al. Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome. Anesthesiology 1995;82(6):1507-11
76. van Heerden PV, Barden A, Michalopoulos N, et al. Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest 2000; 117(3):819-27
77. Dahlem P, van Aalderen WM, de Neef M, et al. Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Crit Care Med 2004;32(4):1055-60
78. Afshari A, Brok J, Moller AM, Wetterslev J. Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Cochrane Database Syst Rev 2010(8):CD007733
79. Bone RC, Slotman G, Maunder R, et al. Randomized double-blind, multicenter study of prostaglandin E1 in patients with the adult respiratory distress syndrome. Prostaglandin E1 Study Group. Chest 1989; 96(1):114-19
80. Abraham E, Baughman R, Fletcher E, et al. TLC C-53 ARDS Study Group. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. Crit Care Med 1999;27(8): 1478-85
81. Vincent JL, Brase R, Santman F, et al. A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med 2001;27(10):1578-83
82. MacIntyre NR, Silver RM, Miller CW, et al. Aerosol delivery in intubated, mechanically ventilated patients. Crit Care Med 1985;13(2):81-4
83. Blitzer ML, Loh E, Roddy MA, et al. Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. J Am Coll Cardiol 1996;28(3):591-6
84. Stamler JS, Loh E, Roddy MA, et al. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994;89(5):2035-40
85. Ghofrani HA, Reichenberger F, Kohstall MG, et al. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann Intern Med 2004;141(3):169-77
86. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353(20):2148-57
87. Shah PS, Ohlsson A. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev 2011(8): CD005494
88. Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 2012;125(2): 324-34
89. Cornet AD, Hofstra JJ, Swart EL, et al. Sildenafil attenuates pulmonary arterial pressure but does not improve oxygenation during ARDS. Intensive Care Med 2010; 36(5):758-64
90. Namachivayam P, Theilen U, Butt WW, et al. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 2006;174(9):1042-7
91. Giacomini M, Borotto E, Bosotti L, et al. Vardenafil and weaning from inhaled nitric oxide: effect on pulmonary hypertension in ARDS. Anaesth Intensive Care 2007;35(1): 91-3
92. Huddleston AJ, Knoderer CA, Morris JL, Ebenroth ES. Sildenafil for the treatment of pulmonary hypertension in pediatric patients. Pediatr Cardiol 2009;30(7):871-82
93. Ware LB, Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001;163(6):1376-83
94. Matthay MA. Alveolar fluid clearance in patients with ARDS: does it make a difference? Chest 2002;122(Suppl 6): 340S-3S
95. Perkins GD, Gao F, Thickett DR. In vivo and in vitro effects of salbutamol on alveolar epithelial repair in acute lung injury. Thorax 2008;63(3):215-20
96. McAuley DF, Frank JA, Fang X, Matthay MA. Clinically relevant concentrations of beta2-Adrenergic agonists stimulate maximal cyclic adenosine monophosphate-dependent airspace fluid clearance and decrease pulmonary edema in experimental acid-induced lung injury. Crit Care Med 2004;32(7):1470-6
97. Perkins GD, McAuley DF, Thickett DR, Gao F. The beta-Agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 2006;173(3):281-7
98. Gao Smith F, Perkins GD, Gates S, et al. Effect of intravenous beta-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet 2012;379(9812):229-35
99. Chang LH, Honiden S, Haithcock JA, et al. Utilization of bronchodilators in ventilated patients without obstructive airways disease. Respir Care 2007;52(2):154-8
100. Ballard J, Lugo RA, Salyer JW. A survey of albuterol administration practices in intubated patients in the neonatal intensive care unit. Respir Care 2002;47(1):31-8
101. Matthay MA, Brower RG, Carson S, et al. Randomized, placebo-controlled clinical trial of an aerosolized beta(2)-Agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011;184(5):561-8
102. Bernard GR, Luce JM, Sprung CL, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987;317(25):1565-70
103. Weigelt JA, Norcross JF, Borman KR, Snyder WH 3rd. Early steroid therapy for respiratory failure. Arch Surg 1985;120(5): 536-40
104. Bone RC, Fisher CJ Jr, Clemmer TP, et al. Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest 1987;92(6):1032-6
105. Henzen C, Suter A, Lerch E, et al. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet 2000; 355(9203):542-5
106. Thompson BT. Glucocorticoids and acute lung injury. Crit Care Med 2003;31(4): S253-7
107. Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006;354(16): 1671-84
108. Meduri GU, Marik PE, Chrousos GP, et al. Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature. Intensive Care Med 2008; 34(1):61-9
109. Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 1998;280(2):159-65
110. Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 2007;131(4):954-63
111. Peter JV, John P, Graham PL, et al. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-Analysis. BMJ 2008;336(7651):1006-9
112. Goh AY, Sekaran D, Roziah M. Corticosteroid rescue in late paediatric acute respiratory distress syndrome. Respirology 1999;4(3):295-7
113. Martinot A, Fourier C, Cremer R, et al. Short-course, high-dose corticosteroid treatment in six children with late ARDS. Pediatr Pulmonol 1997;23(4):314-16
114. Guglani L, Jain S, Lodha R. Methylprednisolone therapy in a child with unresolving ARDS. Indian Pediatr 2006; 43(7):639-42
115. Annane D, Sebille V, Bellissant E. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med 2006;34(1):22-30
116. Marik PE, Pastores SM, Annane D, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008;36(6): 1937-49
117. Marik PE, Meduri GU, Rocco PR, Annane D. Glucocorticoid treatment in acute lung injury and acute respiratory distress syndrome. Crit Care Clin 2011; 27(3):589-607
118. Enhorning G, Shumel B, Keicher L, et al. Phospholipases introduced into the hypophase affect the surfactant film outlining a bubble. J Appl Physiol (1985) 1992;73(3):941-5
119. Holm BA, Enhorning G, Notter RH. A biophysical mechanism by which plasma proteins inhibit lung surfactant activity. Chem Phys Lipids 1988;49(1-2):49-55
120. Holm BA, Keicher L, Liu MY, et al. Inhibition of pulmonary surfactant function by phospholipases. J Appl Physiol (1985) 1991:71(1):317.321
121. Holm BA, Matalon S, Finkelstein JN, Notter RH. Type II pneumocyte changes during hyperoxic lung injury and recovery. J Appl Physiol (1985) 1988:65(6):2672-8
122. Holm BA, Notter RH. Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity. J Appl Physiol (1985) 1987;63(4):1434-42
123. Moses D, Holm BA, Spitale P, et al. Inhibition of pulmonary surfactant function by meconium. Am J Obstet Gynecol 1991; 164(2):477-81
124. Novotny WE, Hudak BB, Matalon S, Holm BA. Hyperoxic lung injury reduces exogenous surfactant clearance in vivo. Am J Respir Crit Care Med 1995;151(6):1843-7
125. Schmidt R, Markart P, Ruppert C, et al. Time-dependent changes in pulmonary surfactant function and composition in acute respiratory distress syndrome due to pneumonia or aspiration. Respir Res 2007;8:55
126. Mastropietro CW, Valentine K. Early administration of intratracheal surfactant (calfactant) after hydrocarbon aspiration. Pediatrics 2011;127(6):e1600-4
127. Volchkov VA, Dubrovskaya VF, Serzhanina VA, et al. Effectiveness of correction of bleomycin-induced lung injury by early and late administration of surfactant-BL. Bull Exp Biol Med 2012; 152(5):580-2
128. Hahn S, Choi HJ, Soll R, Dargaville PA. Lung lavage for meconium aspiration syndrome in newborn infants. Cochrane Database Syst Rev 2013;4:CD003486
129. Bahadue FL, Soll R. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2012;11:CD001456
130. Singh N, Hawley KL, Viswanathan K. Efficacy of porcine versus bovine surfactants for preterm newborns with respiratory distress syndrome: systematic review and meta-Analysis. Pediatrics 2011;128(6): e1588-95
131. Luchetti M, Ferrero F, Gallini C, et al. Multicenter, randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure. Pediatr Crit Care Med 2002;3(3):261-8
132. Luchetti M, Casiraghi G, Valsecchi R, et al. Porcine-derived surfactant treatment of severe bronchiolitis. Acta Anaesthesiol Scand 1998;42(7):805-10
133. Tibby SM, Hatherill M, Wright SM, et al. Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 2000;162(4 Pt 1):1251-6
134. Lewis JF, Brackenbury A. Role of exogenous surfactant in acute lung injury. Crit Care Med 2003;31(4):S324-8
135. Kesecioglu J, Beale R, Stewart TE, et al. Exogenous natural surfactant for treatment of acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2009;180(10):989-94
136. Anzueto A, Baughman RP, Guntupalli KK, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N Engl J Med 1996;334(22):1417-21
137. Willson DF, Thomas NJ, Markovitz BP, et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA 2005; 293(4):470-6
138. Taut FJ, Rippin G, Schenk P, et al. A Search for subgroups of patients with ARDS who may benefit from surfactant replacement therapy: a pooled analysis of five studies with recombinant surfactant protein-C surfactant (Venticute). Chest 2008;134(4):724-32
139. Spragg RG, Lewis JF, Walmrath HD, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med 2004; 351(9):884-92
140. Spragg RG, Taut FJ, Lewis JF, et al. Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury. Am J Respir Crit Care Med 2011;183(8):1055-61
141. Hermon MM, Golej J, Burda G, et al. Surfactant therapy in infants and children: three years experience in a pediatric intensive care unit. Shock 2002;17(4): 247-51
142. Yapicioglu H, Yildizdas D, Bayram I, et al. The use of surfactant in children with acute respiratory distress syndrome: efficacy in terms of oxygenation, ventilation and mortality. Pulm Pharmacol Ther 2003; 16(6):327-33
143. Czaja AS. A critical appraisal of a randomized controlled trial: willson, et al: Effect of exogenous surfactant (calfactant) in pediatric acute lung injury (JAMA 2005, 293: 470-476)
144. Pediatr Crit Care Med 2007;8(1):50-3
145. Duffett M, Choong K, Ng V, et al. Surfactant therapy for acute respiratory failure in children: a systematic review and meta-Analysis. Crit Care 2007;11(3):R66
146. Thomas NJ, Guardia CG, Moya FR, et al. A pilot, randomized, controlled clinical trial of lucinactant, a peptide-containing synthetic surfactant, in infants with acute hypoxemic respiratory failure. Pediatr Crit Care Med 2012;13(6):646-53
147. Willson DF, Thomas NJ, Tamburro R, et al. Pediatric calfactant in acute respiratory distress syndrome trial. Pediatr Crit Care Med 2013;14(7):657-65
148. Zhang LN, Sun JP, Xue XY, Wang JX. Exogenous pulmonary surfactant for acute respiratory distress syndrome in adults: a systematic review and meta-Analysis. Exp Ther Med 2013;5(1):237-42
149. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000;342(18):1301-8
150. Randolph AG, Meert KL, O'Neil ME, et al. The feasibility of conducting clinical trials in infants and children with acute respiratory failure. Am J Respir Crit Care Med 2003;167(10):1334-40
151. Peek GJ, Mugford M, Tiruvoipati R, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 2009;374(9698):1351-63
152. Bein T, Weber-Carstens S, Goldmann A, et al. Lower tidal volume strategy (approximately 3 ml/kg) combined with extracorporeal CO2 removal versus 'conventional' protective ventilation (6 ml/ kg) in severe ARDS: the prospective randomized Xtravent-study. Intensive Care Med 2013;39(5):847-56
153. Trial of Steroids in Pediatric Acute Lung Injury/ARDS. Available from: www. clinicaltrials.gov/ct2/results? term=NCT01274260&Search=Search
154. Effects and Safety of Infusion of Low-Doses of Methylprednisolone in Early ALI and ARDS in Children. Available from: www. clinicaltrials.gov/ct2/results? term=NCT01757899&Search=Search
155. United States National Institutes of Health. Available from: www.nih.gov/
156. Martin R, David JT. Understanding controlled trials: what are pragmatic trials? BMJ 1998;316
157. Cuthbertson BH, Campbell MK, Stott SA, et al. A pragmatic multi-centre randomised controlled trial of fluid loading in high-risk surgical patients undergoing major elective surgery - the FOCCUS study. Crit Care 2011;15(6):R296
158. Campbell NL, Khan BA, Farber M, et al. Improving delirium care in the intensive care unit: the design of a pragmatic study. Trials 2011;12:139
159. Harron K, Lee T, Ball T, et al. Making co-enrolment feasible for randomised controlled trials in paediatric intensive care. PLoS One 2012;7(8):e41791
160. Santschi M, Jouvet P, Leclerc F, et al. Acute lung injury in children: therapeutic practice and feasibility of international clinical trials. Pediatr Crit Care Med 2010;11(6):681-9
161. Luce JM, Montgomery AB, Marks JD, et al. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988;138(1):62-8